This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ImmunoPrecise Antibodies Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

CA$0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	CA$19.24m
Eigenkapital	CA$66.24m
Gesamtverbindlichkeiten	CA$13.70m
Gesamtvermögen	CA$79.94m

Jüngste Berichte zur Finanzlage

We Think ImmunoPrecise Antibodies (CVE:IPA) Needs To Drive Business Growth Carefully

Oct 20

Is ImmunoPrecise Antibodies (CVE:IPA) Using Debt In A Risky Way?

Nov 25

Recent updates

We Think ImmunoPrecise Antibodies (CVE:IPA) Needs To Drive Business Growth Carefully

Oct 20

Earnings Update: ImmunoPrecise Antibodies Ltd. (CVE:IPA) Just Reported And Analysts Are Boosting Their Estimates

Dec 23

Is ImmunoPrecise Antibodies (CVE:IPA) Using Debt In A Risky Way?

Nov 25

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: IPA's short term assets (CA$27.1M) exceed its short term liabilities (CA$5.4M).

Langfristige Verbindlichkeiten: IPA's short term assets (CA$27.1M) exceed its long term liabilities (CA$8.3M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: IPA is debt free.

Schulden abbauen: IPA had no debt 5 years ago.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: IPA has less than a year of cash runway based on its current free cash flow.

Vorhersage Cash Runway: IPA has less than a year of cash runway if free cash flow continues to reduce at historical rates of 36% each year

This company listing is no longer active

ImmunoPrecise Antibodies Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

ImmunoPrecise Antibodies Announces Voluntary Delisting from TSX Venture Exchange

We Think ImmunoPrecise Antibodies (CVE:IPA) Needs To Drive Business Growth Carefully

Is ImmunoPrecise Antibodies (CVE:IPA) Using Debt In A Risky Way?

Recent updates

ImmunoPrecise Antibodies Announces Voluntary Delisting from TSX Venture Exchange

Price target decreased to CA$12.00

We Think ImmunoPrecise Antibodies (CVE:IPA) Needs To Drive Business Growth Carefully

ImmunoPrecise Antibodies Ltd., Annual General Meeting, Dec 13, 2022

First quarter 2023 earnings: EPS and revenues miss analyst expectations

ImmunoPrecise Antibodies Ltd. to Report Q1, 2023 Results on Sep 14, 2022

ImmunoPrecise Antibodies Ltd. to Report Q1, 2023 Results on Sep 14, 2022

Immunoprecise Antibodies Ltd. Announces the Continuing Success of Polytope® Tatx-03 Antibody Combination Therapy to Neutralize Variants of Concern of the Covid-19 Causative Virus

ImmunoPrecise Antibodies Ltd. Announces Executive Changes

Full year 2022 earnings: EPS and revenues exceed analyst expectations

ImmunoPrecise Antibodies Ltd. to Report Q4, 2022 Results on Jul 29, 2022

ImmunoPrecise Antibodies Ltd. Reports the Critical Third-Party Findings of Two IND-Enabling Pre-Clinical Safety Studies

Key Executive exercised options to buy CA$239k worth of stock.

ImmunoPrecise Antibodies Announces Departure of Stefan Lang, Chief Business Officer

Price target decreased to CA$12.00

Insider recently bought CA$8.6m worth of stock

ImmunoPrecise Antibodies Ltd. Shares Outcome of Recent Laboratory Data on Their PolyTope® TATX-03 Antibody Cocktail

Price target decreased to CA$12.00

ImmunoPrecise Antibodies Ltd. Releases Data Demonstrating Strong Neutralizing Potency of PolyTope® TATX-03 Antibody Cocktail Towards the SARS-CoV-2 Omicron Variant

ImmunoPrecise Relocates European Subsidiary to LEED Certified Campus to Continue to Advance its Antibody Research Operations and Environmental Sustainability

Consensus EPS estimates fall by 40%

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Independent Director Brian Lundstrom has left the company

First quarter 2022 earnings released: CA$0.17 loss per share (vs CA$0.038 loss in 1Q 2021)

Full year 2021 earnings released: CA$0.45 loss per share (vs CA$0.36 loss in FY 2020)

ImmunoPrecise Antibodies Ltd. Announces New Results from Its Tatx-03 Polytope™ Therapy

Chief Scientific Officer Yasmina Abdiche has left the company

Chief Scientific Officer Yasmina Abdiche has left the company

Chief Scientific Officer Yasmina Abdiche has left the company

Chief Scientific Officer Yasmina Abdiche has left the company

Chief Scientific Officer Yasmina Abdiche has left the company

Chief Scientific Officer Yasmina Abdiche has left the company

Chief Scientific Officer Yasmina Abdiche has left the company

Chief Scientific Officer Yasmina Abdiche has left the company

Chief Scientific Officer Yasmina Abdiche has left the company

Chief Scientific Officer Yasmina Abdiche has left the company

Chief Scientific Officer Yasmina Abdiche has left the company

Chief Scientific Officer Yasmina Abdiche has left the company

Chief Scientific Officer Yasmina Abdiche has left the company

Chief Scientific Officer Yasmina Abdiche has left the company

ImmunoPrecise Antibodies Ltd. Announces Histopathology Preclinical Data from its Polytopetm Program Confirms Lung Inflammation Reduction

IMMUNOPRECISE to Present Preclinical Data from ImmunoPrecise's Drug Pipeline During the Bio International Partnering Event

ImmunoPrecise Moves SARS-CoV-2 PolyTope™ Cocktail Program’s Path Toward IND Filing

CEO, President & Director recently bought CA$78k worth of stock

Third quarter 2021 earnings released: CA$0.077 loss per share (vs CA$0.046 loss in 3Q 2020)

ImmunoPrecise Antibodies Announces Results from A Comprehensive Screening of 27 Proprietary Anti-SARS-CoV-2 Therapeutic Antibodies

ImmunoPrecise Antibodies Ltd. Announces Data from Preclinical Study of TATX-03 PolyTope Monoclonal Antibody Cocktail Candidate Against Covid-19

ImmunoPrecise Antibodies Ltd. has completed a Follow-on Equity Offering in the amount of $21.739141 million.

Analysts lower EPS estimates to -CA$0.14

New 90-day high: CA$18.11

Second quarter 2021 earnings released: CA$0.03 loss per share

Revenue and earnings beat expectations

Earnings Update: ImmunoPrecise Antibodies Ltd. (CVE:IPA) Just Reported And Analysts Are Boosting Their Estimates

ImmunoPrecise and LiteVax Advance SARS-CoV-2 Vaccine Candidate

ImmunoPrecise Collaboration Enables Preclinical Manufacturing of Lead Antibodies Targeting SARS-CoV-2

Is ImmunoPrecise Antibodies (CVE:IPA) Using Debt In A Risky Way?

Analysts update estimates

Immunoprecise Antibodies Ltd. Selects More Than Ten Unique Monoclonal Antibodies for Further Preclinical Development

ImmunoPrecise and Genmab Enter into a Technology Partnership Targeting Infectious Disease

ImmunoPrecise Antibodies Ltd. and Mila Announce Strategic AI Partnership

ImmunoPrecise Antibodies Ltd. Provides Update on Partnership with the University of Victoria

First quarter earnings released

ImmunoPrecise Antibodies Ltd. Initiates Pre-Clinical Vaccine Trials Against SARS-COV-2

New 90-day high: CA$2.60

ImmunoPrecise Antibodies Ltd. Announces New Multi-Specific SARS-CoV-2 Antibody Collaboration with Zymeworks

New 90-day high - CA$2.05

Full year earnings released - CA$0.073 loss per share

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse